Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity

Diseases of the Colon and Rectum

Volumn 46, Issue 3, 2003, Pages 313-321

  Engarås, Boel ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

CA 242; CA 50; Carcinoembryonic antigen; Colorectal cancer; Postoperative surveillance; Tumor markers

Indexed keywords

CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; CONTRAST SENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; RECURRENT DISEASE;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; COLECTOMY; COLORECTAL NEOPLASMS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037339249     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-004-6548-7     Document Type: Article

References (42)

1. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174-82.
2. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer - preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998;228:59-63.
3. Wanebo HJ, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet 1989;169:479-87.
4. Anonymous. 1997 update of recommendations for the use of tumour markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998;16:793-5.
5. MacKenzie S, O'Dwyer PJ. Surveillance after colorectal cancer resection [letter]. Lancet 2000;355:1095.
6. Shoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.
7. Törnqvist A, Ekelund G, Leandoer L. The value of intensive follow-up after curative resection for colorectal carcinoma. Br J Surg 1982;69:725-8.
8. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997;84:666-9.
9. Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000;355:395-9.
10. Hall NR, Finan PJ, Stephenson BM, Purves DA, Cooper EH. The role of CA 242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 1994;70:549-53.
11. Staab HJ, Anderer FA, Stumpf E, Fischer R. Carcinoembryonic antigen follow-up and selection of patients for second-look operation in management of gastrointestinal carcinoma. J Surg Oncol 1978;10:273-82.
12. Steele G Jr, Zamcheck N, Wilson R, et al. Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg 1980;139:544-8.
13. Martin EW, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985;202:310-7.
14. Engarås B, Hafström L, Kewenter J, Nilsson O, Wedel H. Standard serum concentrations and fluctuations of CEA, CA 50, and CA 242 during twelve months in men and women aged 60-64 years without malignant disease. Eur J Surg 1999;165:110-6.
15. Engarås B, Kewenter J, Nilsson O, Wedel H, Hafström L. Effects of surgery on serum levels of CEA, CA 50 and CA 242 in individuals without malignant disease followed for twelve months. J Tum Mark Oncol 1998;165:110-16. Reprinted 1999;14:45-51.
16. Engarås B, Kewenter J, Nilsson O, Wedel H, Hafström L. Effects of surgery on serum levels of CEA, CA 50 and CA 242 in individuals without malignant disease followed for twelve months. J Tum Mark Oncol 1998;165:110-16. Reprinted 1999;14:45-51.
17. Engarås B, Kewenter J, Nilsson O, Wedel H, Hafström L. CEA, CA 50, and CA 242 in patients surviving colorectal cancer without recurrent disease. Eur J Surg Oncol 2001;27:43-8.
18. Eskelinen M, Pasanen P, Kulju A, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-32.
19. Habib NA, Hershman MJ, Kelly SB, Taylor G, Williamson RC, Wood CB. Clinical experience with CA 50 in the serum of carcinoma patients. Eur J Surg Oncol 1989;15:361-6.
20. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and CEA in digestive tract disease. Br J Cancer 1991;63:636-40.
21. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA 242 in gastro-intestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Br J Cancer 1992;65:215-21.
22. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994;70:487-92.
23. Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA 242 and CA 19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6.
24. Johansson C, Nilsson O, Baeckstrom D, Jansson EL, Lindholm L. Novel epitopes on the CA 50-carrying antigen: chemical and immunochemical studies. Tumour Biol 1991;12:159-70.
25. von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumour markers, CA 242, CA 19-9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-32.
26. Carpelan-Holmström MA, Haglund CH, Järvinen HJ, Roberts PJ. Serum CA 242 and CEA detect different patients with recurrent disease. Anticancer Res 1996;16:981-6.
27. Berge T, Ekelund G, Mellner C, Phil B, Wenckert A. Carcinoma of the colon and rectum in a defined population. An epidemiological, clinical and postmortem investigation of colorectal carcinoma and coexisting benign polyps in Malmo, Sweden. Acta Chir Scand Suppl 1973;438:1-86.
28. Enblad G, Enblad P, Adami HO, Glimelius B, Krusemo U, Pahlman L. Relationship between age and survival in cancer of the colon and rectum with special reference to patients less than 40 years of age. Br J Surg 1990;77:611-6.
29. Sugarbaker PH, Zamcheck N, Moore FD. Assessment of serial CEA assays in postoperative detection of recurrent colorectal cancer. Cancer 1976;38:2310-5.
30. Staab HJ, Anderer FA, Stumpf E, Fischer R. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg 1978;136:322-7.
31. McCall JL, Black RB, Rich CA, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37:875-81.
32. Lucha PA Jr, Rosen L, Olenwine JA, et al. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 1997;40:145-9.
33. Quentmeier A, Schlag P, Hohenberger P, Schwarz V, Abel U. Assessment of serial CEA: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J Surg Oncol 1989;40:112-8.
34. Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996;16:2249-52.
35. Clarke CS, Hine KR, Dykes PW, Whitehead TP, Whitfield AG. Carcinoembryonic antigen and smoking. J R Coll Physicians Lond 1980;14:227-8.
36. Herbeth B, Bagrel A. A study of factors influencing plasma CEA levels in an unselected population. Oncodev Biol Med 1980;1:191-8.
37. Tabor E, Gerety RJ, Needy CF, Elisberg BL, Colon AR, Jones R. CEA levels in asymptomatic adolescents. Eur J Cancer 1981;17:257-8.
38. Foster JH, Lundy J. Liver metastases. Curr Prog Surg 1981;18:158-202.
39. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
40. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992;216:493-504.
41. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991;78:797-801.
42. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272-7.